Hemosure

Hemosure Inc. is a company based in Irwindale, California, specializing in the development and manufacturing of clinical diagnostic test kits and medical devices. The company employs 26 individuals and generates an annual revenue of $50 million. Hemosure is known for its innovative approach to fecal occult blood testing. Their Hemosure® Fecal Occult Blood test (iFOB) has been the leading test in the United States for nearly a decade, recognized for its quality and effectiveness. The company's FDA-cleared Hemosure® Accu-Reader A 100 is an automated immunochemical fecal occult blood diagnostic system, making it the second of its kind to receive FDA clearance, signifying its rigorous testing and commitment to accuracy. This system provides healthcare professionals with increased efficiency and reliability in diagnosing gastrointestinal disorders. The Hemosure® Accu-Reader A 100 offers a rapid 5-minute turnaround time for detecting occult blood in stool samples, potentially enhancing the standard of care in diagnosing these conditions. The company's dedication to advancing medical diagnostics and improving healthcare outcomes is evident in their continuous research and development. For more information on Hemosure's products and services, please visit their website at hemosure.com.